<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Proc (Bayl Univ Med Cent)</journal-id><journal-id journal-id-type="pmc-domain-id">302</journal-id><journal-id journal-id-type="pmc-domain">bumcproc</journal-id><journal-id journal-id-type="publisher-id">bumc</journal-id><journal-title-group><journal-title>Proceedings (Baylor University. Medical Center)</journal-title></journal-title-group><issn pub-type="ppub">0899-8280</issn><issn pub-type="epub">1525-3252</issn><publisher><publisher-name>Baylor University Medical Center</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC1200780</article-id><article-id pub-id-type="pmcid-ver">PMC1200780.1</article-id><article-id pub-id-type="pmcaid">1200780</article-id><article-id pub-id-type="pmcaiid">1200780</article-id><article-id pub-id-type="pmid">16278697</article-id><article-id pub-id-type="doi">10.1080/08998280.2003.11927913</article-id><article-id pub-id-type="publisher-id">bumc0016-0275</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic analysis of rapacuronium and its metabolite during liver transplantation: an assessment of its potential as a pharmacodynamic probe</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Black</surname><given-names initials="RE">Robert E.</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gertler</surname><given-names initials="R">Ralph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wright</surname><given-names initials="PMC">Peter M. C.</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cancemi</surname><given-names initials="MT">Mario T.</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hein</surname><given-names initials="HAT">H.A. Tillmann</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ramsay</surname><given-names initials="MAE">Michael A. E.</given-names></name><degrees>MD, FRCA</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>From the Department of Anesthesiology and Pain Management, Baylor University Medical Center, Dallas, Texas (Black, Cancemi, Hein, Ramsay); Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, Texas (Gertler, Hein, Ramsay); and the Department of Anesthesiology, University of California at San Francisco, San Francisco, California (Wright).</aff><author-notes><corresp><bold>Corresponding author:</bold> Michael A. E. Ramsay, MD, FRCA, Department of Anesthesiology and Pain Management, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, Texas 75246 (e-mail: <email>docram@BaylorHealth.edu</email>).</corresp><fn><p>This study was supported in part by a grant from Organon Inc, West Orange, NJ.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2003</year></pub-date><volume>16</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">121148</issue-id><fpage>275</fpage><lpage>279</lpage><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.BaylorHealth.com/Proceedings" ext-link-type="uri">http://www.BaylorHealth.com/Proceedings</ext-link><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2003</year></date></event><event event-type="pmc-live"><date><day>08</day><month>11</month><year>2005</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-11-04 16:56:15.847"><day>04</day><month>11</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2003, Baylor University Medical Center</copyright-statement><copyright-year>2003</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bumc0016-0275.pdf"/><abstract><p>The liver extracts aminosteroidal neuromuscular blocking drugs. We hypothesized that the duration of action of these drugs might provide a pharmacodynamic probe for assessing graft function during orthotopic liver transplantation. The pharmacokinetics of rapacuronium and its active metabolite, ORG 9488, were prospectively studied in 11 patients. Rapacuronium (1.5 mg/kg) was administered at induction of anesthesia, 2 minutes after clamping the portal vein, and 5 minutes after reper- fusion of the new graft. Blood samples were drawn at intervals, and an independent laboratory analyzed plasma for both rapacuronium and ORG 9488. Rapacuronium's pharmacokinetics were characterized for 3 stages of the transplant using NONMEM software to construct mixed- effects compartmental models. Rapacuronium plasma clearance during the first stage of orthotopic liver transplantation was 7.25 mL/kg/min. Clearance decreased by only 44% during the anhepatic stage, to 3.91 mL/kg/min, and remained decreased after reperfusion. This effect suggests that an alternate clearance pathway exists. The clearance for ORG 9488 was 13.5 mL/kg/min during the paleohepatic and anhepatic stages, but it decreased 83% on reperfusion, suggesting accumulation after reperfusion. This pharmacokinetic analysis suggests that rapacuronium may not be suitable for use as a pharmacodynamic probe.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>